Current Research Studies
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine: REBUILD-2 Study
Rebuild 2 (CGAT)
What is the goal of the study?
This study is being done to see how safe galcanezumab is and how well it will work to help adolescents with chronic migraines.
Who can participate in the study?
This study might be a good fit for you if you: You are 12 to 17 years old at Visit 1 You have a diagnosis of chronic migraine, that is, a headache occurring on 15 or more days per month for at least the last 3 months, which has the features of migraine headache on at least 8 days per month You are up to date on your immunizations